Introduction
Experimental allergic neuritis (EAN) is an au toimmune demyelinating diesease of the peripheral nervous system (PNS) which can be induced in a va riety of species by sensitization with PNS tissue [1] or myelin [2] in Freund's complete adjuvant (FCA). It is recognized as the experimental counterpart of hu man idiopathic polyneuritis [3] (Guillain-Barre syn drome). In experimental allergic encephalomyelitis, the analogous CNS disease, the basic protein of the myelin sheath (MBP) is the causative antigen [4] , PNS myelin also contains MBP (referred to as Pt protein in the PNS) although its encephalitogenic activity is only normally expressed when it is isolated from the myelin [5] . The two major PNS myelin-specific proteins are P0, a glycoprotein of m.w. 28,000, and P2, a basic protein of m.w. 13,000 [5] . Both P0 and P2 have been implicated in the pathology of EAN by the finding of delayed-type hypersensitivity to these two proteins (but not to MBP) in affected guinea pigs [6] , Mononuclear cells which bind P2 protein have also been found in the lymph nodes of rabbits with EAN [7] , Recently, EAN has been in duced in rats with isolated P2 protein [8] .
EAE can be suppressed by repeated injections of MBP in the period following the first development of clinical signs of the disease [9] , By analogy, there fore, it should be possible to suppress EAN with the neuritogenic component of PNS myelin. Here we show that injection of P2 protein at first clinical signs significantly alters the course of EAN in the guinea
Pig-

Materials and M ethods
PNS myelin was isolated from bovine intradural roots [10] , P2 was isolated from 50 mg of an acid ex tract (O.IjV HC1) of delipidated (ethenethanol, 3:2) bovine intradural root myelin by chromatography on G75 Sephadex (2.5 X 69 cm) in 0.1 M acetic acid. The P2 peak at 230-278 ml was collected and rechro matographed under the same conditions. The pu rity of the freeze dried product was assessed by poly acrylamide gel electrophoresis [10] . MBP was isolat ed from bovine brain myelin [11] , EAN was induced by injection of bovine intradural root myelin (1 mg) in an emulsion of saline (0.1 ml) and FCA (0.1 ml; containing 0.5 mg H37 Ra) into the hind feet of Hartley guinea pigs (300-400 g). Treatment was started when there was a loss in weight accompanied by the first signs of mild paraparesis (11-16 days post sensitisation).
A solution or suspension of P2 (5 mg), MBP (5 mg) or PNS myelin (50 mg) in saline (5 ml) was emulsi fied with incomplete Freund's adjuvant (5 ml). 0.1 ml of the emulsion was injected over the nuchal region, and on the ten following days.
Clinical signs were scored on the following scale: 1. weight loss, mild paraparesis; 2. paraparesis (with characteristic "waddling" gait); 3. as 2 with respira tory distress and/or quadriparesis; 4. severe paraparesis/quadriparesis and respiratory distress with up to 45% loss in weight; 5. death or killed when mori bund. Animals were killed when moribund or at 6 -1 0 weeks by exsanguination under ether anaes thesia. Sciatic nerves and spinal cord with spinal roots and dorsal root ganglia (L7 and S I) were removed and fixed in 10% formalin for routine H and E histology.
Results and Discussion
The disease was uniformly fatal in untreated contros after a 6-16 day progressive deterioration (Ta ble). Perivascular infiltration of mononuclear cells and demyelination were seen on histological exami nation of the sciatic nerve and spinal roots (L7, S 1). There was little or no overlap of lesions into the CNS. None of the animals receiving saline and only one receiving MBP showed any clinical improvement over the first five days of treatment. The overall course of disease in these two groups was no differ ent from the untreated control group. In contrast, a definite clinical improvement occurred in the major ity of the animals treated with P2 or PNS myelin. At the end of the treatment period, all four groups (d, e, f, and g) had a significantly (/? = 0.01; Kolmogorov-Smimov test) lower clinical score than the con trol group (a). After therapy was withdrawn, several animals suffered a relapse and followed the normal progressive course to death. However, the percent age mortality in the combined P2-treated animals (50%) was lower than in the combined (a,b,c) control group (94%). The most effective suppression was ob tained with P2 in saline, possibly because here the protein is more readily accessible to the circulating immune system than it is in myelin or in an oily emulsion. Morphological studies are being carried out to assess the degree of residual damage and remyelination in the PNS of the recovered animals.
The mechanism of the suppressive effect of MBP on EAE is thought to involve the interaction of lym phocytes with the injected MBP. Thus it was shown that the passive transfer of EAE with lymph node cells could be blocked by treating the donor animal with MBP [12] . It is not known whether this is simply a "defusing" of MBP-sensitized lymphocytes or whether a more complex process is involved, for example the induction of antigen-specific suppres sor T cells [13] ,
The suppressive effect of P2 on EAN implies that this protein is involved in the pathogenesis of EAN, even though EAN cannot be induced in guinea pigs with P2 in FCA (McDermott, Keith, Madrid unpub lished). This interpretation must be made with caution however since successful suppression of EAE has also been achieved with the non-encephalitogenic co-polymer, Cop-1 [14] , It is possible that more than one PNS myelin component is involved in the induction of EAN. More likely though, the isolation of P2 from its lipid environment in myelin changes its antigenic properties and lessens its neuritogenicity. There is also evidence that isolated P2 protein re gains its neuritogenicity when recombined with gangliosides from peripheral nerve prior to injection [15] , However, the fact that P2 will suppress EAN in dicates that the isolated protein is still capable of interacting with lymphocytes sensitized to myelinbound P2.
This work may have relevance to the treatment of Guillain-Barre syndrome, since sensitivity of lym phocytes to P2 has been demonstrated in patients with this disease [16] . The fatal form of EAN used in this study is perhaps not the best model for assess ment of potential therapy since the human disease has a mortality of around 10-20%. By using lower doses of challenging antigen a more appropriate model could be produced. From the present study, P2 in saline would seem to offer the best prospects for further therapeutic experiments.
